Indian Pharma Sector Seeks Policy Support to Strengthen API Manufacturing and Reduce Import Dependence

Indian Pharma Sector Seeks Policy Support to Strengthen API Manufacturing and Reduce Import Dependence

India’s pharmaceutical industry has called for enhanced policy support to strengthen domestic active pharmaceutical ingredient (API) manufacturing and reduce dependence on imports, industry representatives said in April 2026, as the country seeks to build a more resilient and self-reliant drug supply chain.

The appeal comes amid ongoing concerns over heavy reliance on imports, particularly from select global markets, for key raw materials used in drug production. Industry stakeholders have urged the government to accelerate initiatives aimed at boosting local manufacturing capacity, improving infrastructure, and providing financial incentives to support the sector’s growth.

Concerns Over Import Dependence

India is one of the world’s largest producers of generic medicines, yet it remains significantly dependent on imports for APIs, which are essential components in pharmaceutical formulations. This dependence has raised concerns about supply chain vulnerabilities, especially during global disruptions such as pandemics or geopolitical tensions.

Industry experts warn that over-reliance on external sources for critical inputs can impact drug availability, pricing, and overall healthcare security. Strengthening domestic API production is therefore seen as a strategic priority for ensuring uninterrupted access to medicines.

Stakeholders emphasized that reducing import dependence would not only improve supply chain resilience but also enhance India’s position as a global pharmaceutical hub.

Call for Policy Interventions

Pharmaceutical companies are urging the government to introduce targeted policy measures to support API manufacturing. These include financial incentives, tax benefits, and subsidies to offset higher production costs associated with domestic manufacturing.

Industry leaders have also highlighted the need for faster regulatory approvals, simplified compliance processes, and improved access to funding for API projects. Such measures are expected to encourage investment and accelerate the development of local manufacturing capabilities.

Experts suggest that a stable and supportive policy environment is critical to attracting both domestic and foreign investment in the sector.

Role of Production-Linked Incentive Schemes

The government’s production-linked incentive (PLI) schemes for pharmaceuticals have been identified as a key driver in promoting API manufacturing. These schemes provide financial incentives based on incremental production, encouraging companies to scale up operations.

Industry stakeholders have called for the expansion and extension of these schemes to cover a wider range of APIs and support long-term growth. They also emphasize the importance of timely disbursement of incentives to maintain investor confidence.

Analysts note that PLI schemes have already contributed to increased interest in domestic manufacturing, but further support is needed to achieve self-sufficiency.

Infrastructure and Cost Challenges

One of the major challenges in boosting API manufacturing in India is the higher cost of production compared to some international markets. Factors such as infrastructure limitations, energy costs, and environmental compliance requirements contribute to increased expenses.

Industry representatives have called for the development of dedicated pharmaceutical manufacturing zones with modern infrastructure, shared utilities, and streamlined regulatory processes. Such clusters could help reduce costs and improve efficiency.

Improving logistics and supply chain networks is also seen as essential for supporting large-scale API production.

Environmental and Regulatory Considerations

API manufacturing involves complex chemical processes that require strict adherence to environmental and safety regulations. While compliance is essential, industry stakeholders have highlighted the need for balanced regulations that do not hinder growth.

Authorities are being encouraged to adopt risk-based approaches and provide clear guidelines to facilitate smoother operations. Investments in sustainable manufacturing practices are also being promoted to align with environmental goals.

Experts believe that achieving a balance between regulatory compliance and industrial growth is key to the sector’s success.

Impact on Healthcare and Drug Prices

Strengthening domestic API production is expected to have a positive impact on healthcare by ensuring a stable supply of medicines and reducing price volatility. Lower dependence on imports can help mitigate the impact of global price fluctuations and supply disruptions.

Patients stand to benefit from improved access to affordable medicines, particularly in essential therapeutic areas. Healthcare providers may also experience fewer supply shortages, enhancing treatment continuity.

Industry observers note that a robust API ecosystem is critical for sustaining the growth of India’s pharmaceutical sector.

Global Competitiveness and Export Potential

Enhancing API manufacturing capabilities can also boost India’s competitiveness in the global pharmaceutical market. With stronger domestic production, companies can expand exports and reduce reliance on imported inputs.

India has the potential to become a leading supplier of APIs to global markets, provided it can achieve cost competitiveness and maintain high-quality standards. Strategic investments in research and development, as well as technology adoption, are expected to play a crucial role in achieving this goal.

Experts believe that strengthening API manufacturing can open new opportunities for growth and innovation in the sector.

Industry-Government Collaboration

Collaboration between the pharmaceutical industry and government authorities is seen as essential for addressing challenges and implementing effective solutions. Industry associations are engaging with policymakers to provide recommendations and share insights on sector needs.

Public-private partnerships may also play a role in developing infrastructure, funding projects, and advancing research in API manufacturing. Such collaborations can help bridge gaps and accelerate progress.

Stakeholders emphasize the importance of a coordinated approach to achieve long-term sustainability in the sector.

Future Outlook

The push for stronger API manufacturing reflects India’s broader goal of achieving self-reliance in critical sectors. Continued policy support, investment, and innovation will be essential to realizing this vision.

As global demand for pharmaceuticals continues to grow, the ability to produce APIs domestically will be a key determinant of success for Indian companies. Strengthening this segment can enhance resilience, competitiveness, and overall industry growth.

Experts expect ongoing policy discussions and reforms to shape the future of API manufacturing in India.

Conclusion

The Indian pharmaceutical sector’s call for policy support underscores the urgency of building a robust domestic API manufacturing base to reduce import dependence and ensure long-term supply chain stability.